Skip to main content

Month: September 2024

authID Appoints Identity Industry Veteran Erick Soto as Chief Product Officer

DENVER, Sept. 24, 2024 (GLOBE NEWSWIRE) — authID Inc. (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced the appointment of Erick Soto as Chief Product Officer. Mr. Soto, a seasoned product leader with over 15 years of industry experience, comes to authID after serving as a Chief Product Officer and adviser to successful identity verification providers, financial technology businesses, and neobanks. In his new role, Soto will oversee the evolution of the authID platform for biometrically onboarding and authenticating customers’ employees and consumers. He will direct a robust group of developers and designers working on the continuous improvement of authID’s Proof and Verified product lines to enhance performance, functionality and user experience. Most recently serving...

Continue reading

Intermap’s Team Chosen for Major NGA Data Contract

Luno A budget increased to $290 Million—10x original amount Team CACI named key partner for NGA’s commercial Earth observation program Intermap advances AI/ML innovation in geospatial intelligence DENVER, Sept. 24, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced that, in partnership with CACI, Inc. – Federal (“CACI”), its team has been selected by the National Geospatial-Intelligence Agency (“NGA”) as one of 10 qualified vendors for the Luno A program. Luno A, a new NGA initiative, focuses on providing continually updated, low-latency foundation data to support critical national security indicators. This program represents a significant advancement from the previous Economic Indicator Monitoring...

Continue reading

Worthington Enterprises Reports First Quarter Fiscal 2025 Results

COLUMBUS, Ohio, Sept. 24, 2024 (GLOBE NEWSWIRE) — Worthington Enterprises, Inc. (NYSE: WOR) reported net sales of $257.3 million and net earnings from continuing operations of $24.3 million, or $0.48 per diluted share, for its fiscal 2025 first quarter ended August 31, 2024. This compares to net sales of $311.9 million and net earnings from continuing operations of $26.8 million, or $0.54 per diluted share, in the first quarter of fiscal 2024. On a non-GAAP basis, adjusted net earnings from continuing operations totaled $25.1 million for the first quarter of fiscal 2025, or $0.50 per diluted share, compared to $37.2 million, or $0.75 per diluted share, in the prior year comparable quarter. Reported results reflect the controlling interest portion of continuing operations and were impacted by certain items, as summarized in the...

Continue reading

Farmers & Merchants Bancorp, Inc. Announces 30th Consecutive Annual Increase in Dividend

Regular quarterly dividend increased to $0.22125 per share, or $0.885 per share annualized ARCHBOLD, Ohio, Sept. 24, 2024 (GLOBE NEWSWIRE) — The Board of Directors of Farmers & Merchants Bancorp, Inc., (Nasdaq: FMAO) the holding company of F&M Bank, with total assets of $3.32 billion at June 30, 2024, today announced that it has approved the Company’s quarterly cash dividend of $0.22125 per share. The third-quarter dividend is payable on October 20, 2024, to shareholders of record as of October 4, 2024. The $0.22125 per share cash dividend reflects a $0.00125 per share increase in the quarterly dividend, representing the 30th consecutive annual increase in the Company’s regular dividend payment. Lars B. Eller, President and Chief Executive Officer stated, “I am proud that F&M has established one of the longest track...

Continue reading

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) — Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma’s cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma’s Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105. Kairos Pharma and PreCheck Health Services will utilize advanced molecular diagnostics to corroborate and further develop biomarkers...

Continue reading

Aquafil S.p.A. to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

ARCO, Italy, Sept. 24, 2024 (GLOBE NEWSWIRE) — Aquafil S.p.A. (MI: ECNL) (OTCQX: ECNLF), a pioneer in the circular economy also thanks to the ECONYL® regeneration system, announced today it will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 9:30am ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2024/ or directly at https://app.webinar.net/BE6We3XNbvR. The webcast will also be available for replay following the event. 1×1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with...

Continue reading

Tejon Ranch Co. Names New Senior Vice President- Corporate Communications and Public Affairs

TEJON RANCH, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE: TRC) announced today that Nicholas (Nick) T. Ortiz will join the company as Senior Vice President, Corporate Communications and Public Affairs. In his position Ortiz will oversee the company’s communications, brand image, government affairs key stakeholder engagement activities, and will coordinate with our investor relations team; all in service of the Company’s long-term, growth-oriented goals for the company shareholders.  Ortiz most recently served as Vice President of Small Business Advocacy for the California Chamber of Commerce (CalChamber) the state’s largest, broadest and most effective business association. In his role at CalChamber, Ortiz grew the local chamber relations throughout the state including Southern California. “We’re excited to...

Continue reading

Progress Announces Third Quarter 2024 Financial Results

Progress Q3’24 Tops High End of EstimatesExpects to Close ShareFile Acquisition in Fiscal 2024 BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of AI-powered infrastructure software, today announced financial results for its fiscal third quarter ended August 31, 2024. Third Quarter 2024 Highlights1:Revenue and non-GAAP revenue of $179 million increased 2% year-over-year on both an actual and a constant currency basis. Annualized Recurring Revenue (“ARR”) of $582 million remained relatively flat year-over-year on a constant currency basis. Operating margin was 23% and non-GAAP operating margin was 41%. Diluted earnings per share was $0.65 compared to $0.42 in the same quarter last year, an increase of 55%.  Non-GAAP diluted earnings per share was $1.26 compared to $1.08 in...

Continue reading

ARMOUR Residential REIT, Inc. Announces Guidance for October 2024 Dividend Rate per Common Share

VERO BEACH, Florida, Sept. 24, 2024 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the October 2024 cash dividend for the Company’s Common Stock of $0.24 per Common share. October 2024 Common Stock Dividend InformationMonth   Dividend   Holder of Record Date   Payment DateOctober 2024   $0.24   October 15, 2024   October 30, 2024 Certain Tax MattersARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends...

Continue reading

Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- -The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies- -PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech’s New York-based Immco reference laboratory- DUBLIN, Sept. 24, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has acquired privately held Metabolomics Diagnostics, an Irish deep-tech company, specialized...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.